Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976843 | 0.77 | SLC22A12 (0.45) | HTR6KMT2APOLBPPARG | |
| SCHEMBL6086530 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL5249170 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2APOLB | |
| SCHEMBL31257954 | 0.76 | HTR6 (0.56) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL6087404 | 0.76 | HTR6 (0.56) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL6085799 | 0.76 | HTR6 (0.70) | CDK4CCND1HTR6KMT2ACYP11B1 | |
| SCHEMBL31257964 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL17454529 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2APOLB | |
| SCHEMBL6086178 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2ACYP11B1 | |
| SCHEMBL30577034 | 0.76 | CDK4 (0.55) | CDK4CCND1HTR6KMT2ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | CDK4 570/4885CCND1 265/4885HTR6 2619/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CDK4 1693/4885CCND1 1793/4885HTR6 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.